A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group

Ann Oncol. 1991 Sep;2(8):607-8. doi: 10.1093/oxfordjournals.annonc.a058029.

Abstract

Thirty four patients who were receiving carboplatin 400 mg/m2 for advanced epithelial ovarian cancer were treated with ondansetron antiemetic prophylaxis. Ondansetron was given as 4 mg oral +4 mg iv 30 minutes prior to carboplatin followed by 8 mg oral tds for 5 days. Of the evaluable patients complete or major control of emesis on day one was achieved in 94% of previously untreated patients and 81% of patients refractory to conventional antiemetic therapy. For the 5 day period as a whole 88% of untreated patients and 69% of those with refractory emesis reported complete or major control of nausea and vomiting. Fifteen patients noted no side effects with mild headache (30%) and constipation (21%) the most frequent problems in the remainder. Ondansetron is effective antiemetic prophylaxis for carboplatin chemotherapy and should allow the majority of these patients to be managed on an out-patient basis.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Carboplatin / adverse effects*
  • Carboplatin / therapeutic use
  • Epithelium / pathology
  • Female
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Middle Aged
  • Nausea / drug therapy*
  • Ondansetron
  • Ovarian Neoplasms / drug therapy*
  • Vomiting / drug therapy*

Substances

  • Imidazoles
  • Ondansetron
  • Carboplatin